As of June 21, 2025, Liberty Health Sciences Inc (LHS.CN) reports a Gross Margin of 113.44%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Liberty Health Sciences Inc's Gross Margin
Over recent years, Liberty Health Sciences Inc's Gross Margin has shown a moderate pattern. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2020-02-29 | 113.44% |
| 2019-02-28 | 135.09% |
| 2018-02-28 | 159.42% |
This gradual decrease highlights how Liberty Health Sciences Inc manages its operational efficiency and pricing power over time.
Comparing Liberty Health Sciences Inc's Gross Margin to Peers
To better understand Liberty Health Sciences Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Liberty Health Sciences Inc (LHS.CN) | 113.44% |
| Onconova Therapeutics Inc (ONTX) | 7775.20% |
| TherapeuticsMD Inc (TXMD) | 100.00% |
| Chiasma Inc (CHMA) | 94.59% |
| Marinus Pharmaceuticals Inc (MRNS) | 93.76% |
| Strongbridge Biopharma plc (SBBP) | 92.81% |
Compared to its competitors, Liberty Health Sciences Inc's Gross Margin is among the highest compared to peers, indicating superior product pricing power or cost efficiency in production.